Literature DB >> 20371035

International consensus statement on major depressive disorder.

David J Nutt1, Jonathan R T Davidson, Alan J Gelenberg, Teruhiko Higuchi, Shigenobu Kanba, Oğuz Karamustafalioğlu, George I Papakostas, Kaoru Sakamoto, Takeshi Terao, Mingyuan Zhang.   

Abstract

Because considerable variability exists between countries in the management of major depressive disorder, experts in psychiatry gathered for the International Consensus Group on Depression to outline a universal treatment algorithm for this illness. The experts decided to adapt the existing treatment algorithm developed in Japan and discuss strategies for clinical issues that have been problematic in some countries. Specific recommendations were made by the consensus group for screening for, diagnosing, and treating depression, which include periodically screening all patients for depression, completing a differential diagnosis of depression, referring to a psychiatric specialist if needed, establishing a therapeutic alliance with patients and their families, choosing and optimizing the dose of appropriate antidepressants based on individual patient's needs, and incorporating nonpharmacologic treatment strategies as necessary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371035     DOI: 10.4088/JCP.9058se1c.08gry

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

Review 1.  The efficacy and tolerability of bupropion in the treatment of major depressive disorder.

Authors:  Ricardo Moreira
Journal:  Clin Drug Investig       Date:  2011-10-19       Impact factor: 2.859

2.  Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications.

Authors:  Greta A Bushnell; Til Stürmer; Alice White; Virginia Pate; Sonja A Swanson; Deborah Azrael; Matthew Miller
Journal:  J Affect Disord       Date:  2016-02-09       Impact factor: 4.839

3.  Major depression in primary care: making the diagnosis.

Authors:  Chung Wai Mark Ng; Choon How How; Yin Ping Ng
Journal:  Singapore Med J       Date:  2016-11       Impact factor: 1.858

Review 4.  Managing depression in primary care.

Authors:  Chung Wai Mark Ng; Choon How How; Yin Ping Ng
Journal:  Singapore Med J       Date:  2017-08       Impact factor: 1.858

5.  Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.

Authors:  Patrice Boyer; Cécile Vialet; Eunhee Hwang; Karen A Tourian
Journal:  Prim Care Companion CNS Disord       Date:  2015-08-27

Review 6.  Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 7.  Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults.

Authors:  Glenda MacQueen; Pasqualina Santaguida; Homa Keshavarz; Natalia Jaworska; Mitchell Levine; Joseph Beyene; Parminder Raina
Journal:  Can J Psychiatry       Date:  2016-09-24       Impact factor: 4.356

Review 8.  Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder.

Authors:  Ashwin A Patkar; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

9.  Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response.

Authors:  Daniel E Casey; Kimberly K Laubmeier; Sabrina Vogel Marler; Robert A Forbes; Ross A Baker
Journal:  Prim Care Companion CNS Disord       Date:  2012-05-31

10.  Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.

Authors:  Greta A Bushnell; Til Stürmer; Sonja A Swanson; Alice White; Deborah Azrael; Virginia Pate; Matthew Miller
Journal:  Psychiatr Serv       Date:  2015-11-16       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.